<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LYRICA- pregabalin capsule </strong><br>A-S Medication Solutions LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LYRICA safely and effectively. See full prescribing information for LYRICA.<br><br> LYRICA (pregabalin) Capsules, CV<br> LYRICA (pregabalin) Oral Solution, CV<br> Initial U.S. Approval: 2004</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><span class="Bold">LYRICA</span> is indicated for: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span>  (DPN) (<a href="#S1">1</a>)</li>
<li>Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> (PHN) (<a href="#S1">1</a>)</li>
<li>Adjunctive therapy for adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<a href="#S1">1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> (<a href="#S1">1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span>  (<a href="#S1">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul>
<li>For all indications, begin dosing at 150 mg/day. (<a href="#S2.1">2.1</a>,<a href="#S2.2"> 2.2</a>,<a href="#S2.3"> 2.3</a>,<a href="#S2.4"> 2.4</a>,<a href="#S2.5"> 2.5</a>) </li>
<li>Dosing recommendations:</li>
</ul>
<table width="60%">
<col align="left" valign="bottom" width="33%">
<col align="left" valign="bottom" width="34%">
<col align="left" valign="bottom" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">INDICATION</th>
<th class="Rrule" align="left">Dosing Regimen</th>
<th class="Rrule" align="left">Maximum Dose</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">DPN <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (<a href="#S2.1">2.1</a>)</td>
<td class="Rrule" align="left">3 divided doses per day</td>
<td class="Rrule" align="left">300 mg/day within 1 week</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PHN (<a href="#S2.2">2.2</a>)</td>
<td class="Rrule" align="left">2 or 3 divided doses per day</td>
<td class="Rrule" align="left">300 mg/day within 1 week. Maximum dose of 600 mg/day.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Adjunctive Therapy for Adult Patients with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> (<a href="#S2.3">2.3</a>)</td>
<td class="Rrule" align="left">2 or 3 divided doses per day</td>
<td class="Rrule" align="left">Maximum dose of 600 mg/day.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> (<a href="#S2.4">2.4</a>)</td>
<td class="Rrule" align="left">2 divided doses per day</td>
<td class="Rrule" align="left">300 mg/day within 1 week.<br>Maximum dose of 450 mg/day.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">Spinal Cord Injury</span> (<a href="#S2.5">2.5</a>)</td>
<td class="Rrule" align="left">2 divided doses per day</td>
<td class="Rrule" align="left">300 mg/day within 1 week. Maximum dose of 600 mg/day.</td>
</tr>
</tbody>
</table>
<ul>
<li>Dose should be adjusted in patients with reduced renal function. (<a href="#S2.6">2.6</a>)</li>
<li>Oral Solution Concentration and Dispensing (<a href="#S2.7">2.7</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li> Capsules: 25mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. (<a href="#S3">3</a>)</li>
<li> Oral Solution: 20 mg/ mL. (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pregabalin or any of its components. (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> (e.g. <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the throat, head and neck) can occur, and may be associated with life-threatening respiratory compromise requiring emergency treatment. Discontinue LYRICA immediately in these cases. (<a href="#S5.1">5.1</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (e.g. <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>) can occur. Discontinue LYRICA immediately in these patients. (<a href="#S5.2">5.2</a>)</li>
<li> Increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency may occur in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders if LYRICA is rapidly discontinued. Withdraw LYRICA gradually over a minimum of 1 week. (<a href="#S5.3">5.3</a>)</li>
<li> Antiepileptic drugs, including LYRICA, increase the risk of suicidal thoughts or behavior. (<a href="#S5.4">5.4</a>)</li>
<li> LYRICA may cause <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. Exercise caution when co-administering LYRICA and thiazolidinedione antidiabetic agents. (<a href="#S5.5">5.5</a>)</li>
<li>LYRICA may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and impair patients' ability to drive or operate machinery.(<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 5% and twice placebo) are <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span> (primarily difficulty with concentration/attention). (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (800) 438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li>To enroll in the North American Antiepileptic Drug Pregnancy Registry call 1-888-233-2334 (toll free). (<a href="#S8.1">8.1</a> )</li></ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Adjunctive Therapy for Adult Patients with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> </a></h2>
<h2><a href="#section-2.5" class="toc">2.5 <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">Spinal Cord Injury</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Oral Solution Concentration and Dispensing</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Withdrawal of Antiepileptic Drugs (AEDs)</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Abrupt or Rapid Discontinuation</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Tumorigenic Potential</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Ophthalmological Effects</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Creatine Kinase Elevations</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Decreased Platelet Count</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 PR Interval Prolongation</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Adjunctive Therapy for Adult Patients with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-14.4" class="toc">14.4 Management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> </a></h2>
<h2><a href="#section-14.5" class="toc">14.5 Management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">Spinal Cord Injury</span></a></h2>
<h1><a href="#section-15" class="toc">HOW SUPPLIED</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Medication Guide</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Suicidal Thinking and Behavior</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Abrupt or Rapid Discontinuation</a></h2>
<h2><a href="#section-16.8" class="toc">17.8 Ophthalmological Effects</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Creatine Kinase Elevations</a></h2>
<h2><a href="#section-16.10" class="toc">17.10 CNS Depressants</a></h2>
<h2><a href="#section-16.11" class="toc">17.11 Alcohol</a></h2>
<h2><a href="#section-16.12" class="toc">17.12 Use in Pregnancy</a></h2>
<h2><a href="#section-16.13" class="toc">17.13 Male Fertility</a></h2>
<h2><a href="#section-16.14" class="toc">17.14 Dermatopathy</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">LYRICA is indicated for:</p>
<ul>
<li><span class="Bold">Management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span></span></li>
<li><span class="Bold">Management of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span></span></li>
<li><span class="Bold">Adjunctive therapy for adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></span></li>
<li><span class="Bold">Management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span></span></li>
<li><span class="Bold">Management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">LYRICA is given orally with or without food.</p>
<p>When discontinuing LYRICA, taper gradually over a minimum of 1 week.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathy</span></h2>
<p class="First">The maximum recommended dose of LYRICA is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function <span class="Italics">[see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>.</p>
<p>Although LYRICA was also studied at 600 mg/day, there is no evidence that this dose confers additional significant benefit and this dose was less well tolerated. In view of the dose-dependent adverse reactions, treatment with doses above 300 mg/day is not recommended <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2 Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></h2>
<p class="First">The recommended dose of LYRICA is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 75 mg two times a day, or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function <span class="Italics">[see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>.</p>
<p>Patients who do not experience sufficient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief following 2 to 4 weeks of treatment with 300 mg/day, and who are able to tolerate LYRICA, may be treated with up to 300 mg two times a day, or 200 mg three times a day (600 mg/day). In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, reserve dosing above 300 mg/day for those patients who have on-going <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and are tolerating 300 mg daily<span class="Italics"> [see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>2.3 Adjunctive Therapy for Adult Patients with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in adults. Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related. Administer the total daily dose in two or three divided doses. In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Based on individual patient response and tolerability, the dose may be increased to a maximum dose of 600 mg/day.</p>
<p>Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function <span class="Italics">[see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>.</p>
<p>The effect of dose escalation rate on the tolerability of LYRICA has not been formally studied.</p>
<p>The efficacy of add-on LYRICA in patients taking gabapentin has not been evaluated in controlled trials. Consequently, dosing recommendations for the use of LYRICA with gabapentin cannot be offered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>2.4 Management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> </h2>
<p class="First">The recommended dose of LYRICA for <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> is 300 to 450 mg/day. Begin dosing at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Although LYRICA was also studied at 600 mg/day, there is no evidence that this dose confers additional benefit and this dose was less well tolerated. In view of the dose-dependent adverse reactions, treatment with doses above 450 mg/day is not recommended <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function <span class="Italics">[see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.5"></a><p></p>
<h2>2.5 <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">Spinal Cord Injury</span></h2>
<p class="First">The recommended dose range of LYRICA for the treatment of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span> is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate LYRICA may be treated with up to 300 mg two times a day <span class="Italics">[see<a href="#S14.5"> Clinical Studies (14.5)</a>]</span>. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function <span class="Italics">[see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6"></a><p></p>
<h2>2.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In view of dose-dependent adverse reactions and since LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function. Base the dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on creatinine clearance (CLcr), as indicated in Table 1. To use this dosing table, an estimate of the patient's CLcr in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation:</p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-01.jpg"></div>
<p>Next, refer to the Dosage and Administration section to determine the recommended total daily dose based on indication, for a patient with normal renal function (CLcr ≥60 mL/min). Then refer to Table 1 to determine the corresponding renal adjusted dose.</p>
<p>(For example: A patient initiating LYRICA therapy for postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> with normal renal function (CLcr ≥60 mL/min), receives a total daily dose of 150 mg/day pregabalin. Therefore, a renal impaired patient with a CLcr of 50 mL/min would receive a total daily dose of 75 mg/day pregabalin administered in two or three divided doses.)</p>
<p>For patients undergoing hemodialysis, adjust the pregabalin daily dose based on renal function. In addition to the daily dose adjustment, administer a supplemental dose immediately following every 4-hour hemodialysis treatment (see <a href="#table1">Table 1</a>).</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1. Pregabalin Dosage Adjustment Based on Renal Function</span></caption>
<col align="center" valign="top" width="36%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="22%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Creatinine Clearance (CLcr)<br>(mL/min)</th>
<th class="Lrule" align="center" colspan="4">Total Pregabalin Daily Dose<br>(mg/day)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Lrule Rrule" align="center" valign="middle">Dose Regimen</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">TID= Three divided doses; BID = Two divided doses; QD = Single daily dose.</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Supplementary dose is a single additional dose.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Botrule Lrule Toprule" align="center">≥60</td>
<td class="Botrule Lrule Toprule" align="center">150</td>
<td class="Botrule Lrule Toprule" align="center">300</td>
<td class="Botrule Lrule Toprule" align="center">450</td>
<td class="Botrule Lrule Toprule" align="center">600</td>
<td class="Lrule Rrule" align="center">BID or TID</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">30–60</td>
<td class="Lrule" align="center">75</td>
<td class="Lrule" align="center">150</td>
<td class="Lrule" align="center">225</td>
<td class="Lrule" align="center">300</td>
<td class="Lrule Rrule" align="center">BID or TID</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">15–30</td>
<td class="Lrule" align="center">25–50</td>
<td class="Lrule" align="center">75</td>
<td class="Lrule" align="center">100–150</td>
<td class="Lrule" align="center">150</td>
<td class="Lrule Rrule" align="center">QD or BID</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">&lt;15</td>
<td class="Lrule" align="center">25</td>
<td class="Lrule" align="center">25–50</td>
<td class="Lrule" align="center">50–75</td>
<td class="Lrule" align="center">75</td>
<td class="Lrule Rrule" align="center">QD</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="6">Supplementary dosage following hemodialysis (mg)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="6">Patients on the 25 mg QD regimen: take one supplemental dose of 25 mg or 50 mg</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="6">Patients on the 25–50 mg QD regimen: take one supplemental dose of 50 mg or 75 mg</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="6">Patients on the 50–75 mg QD regimen: take one supplemental dose of 75 mg or 100 mg</td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="6">Patients on the 75 mg QD regimen: take one supplemental dose of 100 mg or 150 mg</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.7"></a><p></p>
<h2>2.7 Oral Solution Concentration and Dispensing</h2>
<p class="First">The oral solution is 20 mg pregabalin per milliliter (mL) and prescriptions should be written in milligrams (mg). The pharmacist will calculate the applicable dose in mL for dispensing (e.g., 150 mg equals 7.5 mL oral solution).</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150  mg, 200 mg, 225 mg, and 300 mg</p>
<p>Oral Solution: 20 mg/mL</p>
<p><span class="Italics">[see<a href="#S11"> Description (11) </a>and<a href="#S16"> How Supplied/Storage and Handling (16)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">LYRICA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pregabalin or any of its components. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred in patients receiving pregabalin therapy.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in patients during initial and chronic treatment with LYRICA. Specific symptoms included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There were reports of life-threatening <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with respiratory compromise requiring emergency treatment. Discontinue LYRICA immediately in patients with these symptoms.</p>
<p>Exercise caution when prescribing LYRICA to patients who have had a previous episode of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. In addition, patients who are taking other drugs associated with <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> in patients shortly after initiation of treatment with LYRICA. Adverse reactions included skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. Discontinue LYRICA immediately in patients with these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 Withdrawal of Antiepileptic Drugs (AEDs)</h2>
<p class="First">As with all AEDs, withdraw LYRICA gradually to minimize the potential of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders. If LYRICA is discontinued, taper the drug gradually over a minimum of 1 week.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Antiepileptic drugs (AEDs), including LYRICA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Monitor patients treated with any AED for any indication for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5–100 years) in the clinical trials analyzed.</p>
<p>Table 2 shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2. Risk by indication for antiepileptic drugs in the pooled analysis</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Indication</th>
<th class="Rrule" align="left">Placebo Patients with Events Per 1000 Patients</th>
<th class="Rrule" align="left">Drug Patients with Events Per 1000 Patients</th>
<th class="Rrule" align="left">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th class="Rrule" align="left">Risk Difference: Additional Drug Patients with Events Per 1000 Patients</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center">3.4</td>
<td class="Rrule" align="center">3.5</td>
<td class="Rrule" align="center">2.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Psychiatric</td>
<td class="Rrule" align="center">5.7</td>
<td class="Rrule" align="center">8.5</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Other</td>
<td class="Rrule" align="center">1.0</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">1.9</td>
<td class="Rrule" align="center">0.9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Total</td>
<td class="Rrule" align="center">2.4</td>
<td class="Rrule" align="center">4.3</td>
<td class="Rrule" align="center">1.8</td>
<td class="Rrule" align="center">1.9</td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<p>Anyone considering prescribing LYRICA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<p>Inform patients, their caregivers, and families that LYRICA and other AEDs increase the risk of suicidal thoughts and behavior and advise them of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Report behaviors of concern immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></h2>
<p class="First">LYRICA treatment may cause <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. In short-term trials of patients without clinically significant heart or <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>, there was no apparent association between <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and cardiovascular complications such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> was not associated with laboratory changes suggestive of deterioration in renal or hepatic function.</p>
<p>In controlled clinical trials the incidence of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> was 6% in the LYRICA group compared with 2% in the placebo group. In controlled clinical trials, 0.5% of LYRICA patients and 0.2% placebo patients withdrew due to <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p>Higher frequencies of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> were observed in patients taking both LYRICA and a thiazolidinedione antidiabetic agent compared to patients taking either drug alone. The majority of patients using thiazolidinedione antidiabetic agents in the overall safety database were participants in studies of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span>. In this population, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> was reported in 3% (2/60) of patients who were using thiazolidinedione antidiabetic agents only, 8% (69/859) of patients who were treated with LYRICA only, and 19% (23/120) of patients who were on both LYRICA and thiazolidinedione antidiabetic agents. Similarly, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reported in 0% (0/60) of patients on thiazolidinediones only; 4% (35/859) of patients on LYRICA only; and 7.5% (9/120) of patients on both drugs.</p>
<p>As the thiazolidinedione class of antidiabetic drugs can cause <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and/or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, possibly exacerbating or leading to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, exercise caution when co-administering LYRICA and these agents.</p>
<p>Because there are limited data on <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> patients with New York Heart Association (NYHA) Class III or IV cardiac status, exercise caution when using LYRICA in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">LYRICA may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Inform patients that LYRICA-related <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may impair their ability to perform tasks such as driving or operating machinery <span class="Italics">[see<a href="#S17.5"> Patient Counseling Information (17.5)</a>]</span>.</p>
<p>In the LYRICA controlled trials, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was experienced by 30% of LYRICA-treated patients compared to 8% of placebo-treated patients; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was experienced by 23% of LYRICA-treated patients compared to 8% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> generally began shortly after the initiation of LYRICA therapy and occurred more frequently at higher doses. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were the adverse reactions most frequently leading to withdrawal (4% each) from controlled studies. In LYRICA-treated patients reporting these adverse reactions in short-term, controlled studies, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> persisted until the last dose in 30% and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> persisted until the last dose in 42% of patients <span class="Italics">[see<a href="#S7"> Drug Interactions (7)</a>]</span>. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></h2>
<p class="First">LYRICA treatment may cause <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. In LYRICA controlled clinical trials of up to 14 weeks, a gain of 7% or more over baseline weight was observed in 9% of LYRICA-treated patients and 2% of placebo-treated patients. Few patients treated with LYRICA (0.3%) withdrew from controlled trials due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. LYRICA associated <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was related to dose and duration of exposure, but did not appear to be associated with baseline BMI, gender, or age. <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> was not limited to patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> <span class="Italics">[see<a href="#S5.5"> Warnings and Precautions (5.5)</a>]</span>.</p>
<p>Although <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was not associated with clinically important changes in blood pressure in short-term controlled studies, the long-term cardiovascular effects of LYRICA-associated <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> are unknown.</p>
<p>Among diabetic patients, LYRICA-treated patients gained an average of 1.6 kg (range: -16 to 16 kg), compared to an average 0.3 kg (range: -10 to 9 kg) <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in placebo patients. In a cohort of 333 diabetic patients who received LYRICA for at least 2 years, the average <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 5.2 kg.</p>
<p>While the effects of LYRICA-associated <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> on glycemic control have not been systematically assessed, in controlled and longer-term open label clinical trials with diabetic patients, LYRICA treatment did not appear to be associated with loss of glycemic control (as measured by HbA<span class="Sub">1C</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>5.8 Abrupt or Rapid Discontinuation</h2>
<p class="First">Following abrupt or rapid discontinuation of LYRICA, some patients reported symptoms including <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Taper LYRICA gradually over a minimum of 1 week rather than discontinuing the drug abruptly. 								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2>5.9 Tumorigenic Potential</h2>
<p class="First">In standard preclinical <span class="Italics">in vivo</span> lifetime carcinogenicity studies of LYRICA, an unexpectedly high incidence of <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcoma</span> was identified in two different <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mice <span class="Italics">[see<a href="#S13.1"> Nonclinical Toxicology (13.1)</a>]</span>. The clinical significance of this finding is unknown. Clinical experience during LYRICA's premarketing development provides no direct means to assess its potential for inducing tumors in humans.</p>
<p>In clinical studies across various patient populations, comprising 6396 patient-years of exposure in patients &gt;12 years of age, new or worsening-preexisting tumors were reported in 57 patients. Without knowledge of the background incidence and recurrence in similar populations not treated with LYRICA, it is impossible to know whether the incidence seen in these cohorts is or is not affected by treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.10"></a><p></p>
<h2>5.10 Ophthalmological Effects</h2>
<p class="First">In controlled studies, a higher proportion of patients treated with LYRICA reported <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> (7%) than did patients treated with placebo (2%), which resolved in a majority of cases with continued dosing. Less than 1% of patients discontinued LYRICA treatment due to vision-related events (primarily <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>).</p>
<p>Prospectively planned ophthalmologic testing, including visual acuity testing, formal visual field testing and dilated funduscopic examination, was performed in over 3600 patients. In these patients, visual acuity was reduced in 7% of patients treated with LYRICA, and 5% of placebo-treated patients. Visual field changes were detected in 13% of LYRICA-treated, and 12% of placebo-treated patients. Funduscopic changes were observed in 2% of LYRICA-treated and 2% of placebo-treated patients.</p>
<p>Although the clinical significance of the ophthalmologic findings is unknown, inform patients to notify their physician if changes in vision occur. If <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> persists, consider further assessment. Consider more frequent assessment for patients who are already routinely monitored for ocular conditions <span class="Italics">[see<a href="#S17.8"> Patient Counseling Information (17.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.11"></a><p></p>
<h2>5.11 Creatine Kinase Elevations</h2>
<p class="First">LYRICA treatment was associated with creatine kinase elevations. Mean changes in creatine kinase from baseline to the maximum value were 60 U/L for LYRICA-treated patients and 28 U/L for the placebo patients. In all controlled trials across multiple patient populations, 1.5% of patients on LYRICA and 0.7% of placebo patients had a value of creatine kinase at least three times the upper limit of normal. Three LYRICA treated subjects had events reported as <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> in premarketing clinical trials. The relationship between these <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> events and LYRICA is not completely understood because the cases had documented factors that may have caused or contributed to these events. Instruct patients to promptly report unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if these muscle symptoms are accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Discontinue treatment with LYRICA if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected or if markedly elevated creatine kinase levels occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.12"></a><p></p>
<h2>5.12 Decreased Platelet Count</h2>
<p class="First">LYRICA treatment was associated with a decrease in platelet count. LYRICA-treated subjects experienced a mean maximal decrease in platelet count of 20 × 10<span class="Sup">3</span>/µL, compared to 11 × 10<span class="Sup">3</span>/µL in placebo patients. In the overall database of controlled trials, 2% of placebo patients and 3% of LYRICA patients experienced a potentially clinically significant decrease in platelets, defined as 20% below baseline value and &lt;150 × 10<span class="Sup">3</span>/µL. A single LYRICA treated subject developed severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with a platelet count less than 20 × 10<span class="Sup">3</span>/ µL. In randomized controlled trials, LYRICA was not associated with an increase in <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>-related adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.13"></a><p></p>
<h2>5.13 PR Interval Prolongation</h2>
<p class="First">LYRICA treatment was associated with PR interval prolongation. In analyses of clinical trial ECG data, the mean PR interval increase was 3–6 msec at LYRICA doses ≥300 mg/day. This mean change difference was not associated with an increased risk of PR increase ≥25% from baseline, an increased percentage of subjects with on-treatment PR &gt;200 msec, or an increased risk of adverse reactions of second or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span>.</p>
<p>Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications. However, these analyses cannot be considered definitive because of the limited number of patients in these categories.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In all controlled and uncontrolled trials across various patient populations during the premarketing development of LYRICA, more than 10,000 patients have received LYRICA. Approximately 5000 patients were treated for 6 months or more, over 3100 patients were treated for 1 year or longer, and over 1400 patients were treated for at least 2 years.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Most Commonly Leading to Discontinuation in All Premarketing Controlled Clinical Studies</span></p>
<p>In premarketing controlled trials of all populations combined, 14% of patients treated with LYRICA and 7% of patients treated with placebo discontinued prematurely due to adverse reactions. In the LYRICA treatment group, the adverse reactions most frequently leading to discontinuation were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (4%) and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (4%). In the placebo group, 1% of patients withdrew due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and &lt;1% withdrew due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Other adverse reactions that led to discontinuation from controlled trials more frequently in the LYRICA group compared to the placebo group were <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (1% each).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Most Common Adverse Reactions in All Premarketing Controlled Clinical Studies</span></p>
<p>In premarketing controlled trials of all patient populations combined, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and "<span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>" (primarily difficulty with concentration/attention) were more commonly reported by subjects treated with LYRICA than by subjects treated with placebo (≥5% and twice the rate of that seen in placebo).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Controlled Studies with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathy</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3.1"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Leading to Discontinuation</span></p>
<p>In clinical trials in patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span>, 9% of patients treated with LYRICA and 4% of patients treated with placebo discontinued prematurely due to adverse reactions. In the LYRICA treatment group, the most common reasons for discontinuation due to adverse reactions were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (3%) and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (2%). In comparison, &lt;1% of placebo patients withdrew due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Other reasons for discontinuation from the trials, occurring with greater frequency in the LYRICA group than in the placebo group, were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. Each of these events led to withdrawal in approximately 1% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3.2"></a><p></p>
<p class="First"><span class="Italics">Most Common Adverse Reactions</span></p>
<p>Table 3 lists all adverse reactions, regardless of causality, occurring in ≥1% of patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic neuropathy</span> in the combined LYRICA group for which the incidence was greater in this combined LYRICA group than in the placebo group. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of "mild" or "moderate".</p>
<a name="table3"></a><table width="85%">
<caption><span>Table 3. Treatment-emergent adverse reaction incidence in controlled trials in <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span> (events in at least 1% of all LYRICA-treated patients and at least numerically more in all LYRICA than in the placebo group)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">Body system<br>Preferred term</th>
<th class="Rrule" align="center">75 mg/day</th>
<th class="Rrule" align="center">150 mg/day</th>
<th class="Rrule" align="center">300 mg/day</th>
<th class="Rrule" align="center">600 mg/day</th>
<th class="Rrule" align="center">All PGB<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">[N=77]<br>%</th>
<th class="Rrule" align="center">[N=212]<br>%</th>
<th class="Rrule" align="center">[N=321]<br>%</th>
<th class="Rrule" align="center">[N=369]<br>%</th>
<th class="Rrule" align="center">[N=979]<br>%</th>
<th class="Rrule" align="center">[N=459]<br>%</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>PGB: pregabalin</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span> primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span>.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>Investigator term; summary level term is <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Body as a whole</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Digestive system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Metabolic and <br>nutritional disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Nervous system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Special senses</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurry vision</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline">Controlled Studies in Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.1"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Leading to Discontinuation</span></p>
<p>In clinical trials in patients with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, 14% of patients treated with LYRICA and 7% of patients treated with placebo discontinued prematurely due to adverse reactions. In the LYRICA treatment group, the most common reasons for discontinuation due to adverse reactions were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (4%) and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3%). In comparison, less than 1% of placebo patients withdrew due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Other reasons for discontinuation from the trials, occurring in greater frequency in the LYRICA group than in the placebo group, were <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (2%), as well as <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, and <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span> (1% each).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4.2"></a><p></p>
<p class="First"><span class="Italics">Most Common Adverse Reactions</span></p>
<p>Table 4 lists all adverse reactions, regardless of causality, occurring in ≥ 1% of patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> in the combined LYRICA group for which the incidence was greater in this combined LYRICA group than in the placebo group. In addition, an event is included, even if the incidence in the all LYRICA group is not greater than in the placebo group, if the incidence of the event in the 600 mg/day group is more than twice that in the placebo group. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of "mild" or "moderate". Overall, 12.4% of all pregabalin-treated patients and 9.0% of all placebo-treated patients had at least one severe event while 8% of pregabalin-treated patients and 4.3% of placebo-treated patients had at least one severe treatment-related adverse event.</p>
<a name="table4"></a><table width="85%">
<caption><span>Table 4. Treatment-emergent adverse reaction incidence in controlled trials in <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> (events in at least 1% of all LYRICA-treated patients and at least numerically more in all LYRICA than in the placebo group)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">Body system<br>Preferred term</th>
<th class="Rrule" align="center">75 mg/d</th>
<th class="Rrule" align="center">150 mg/d</th>
<th class="Rrule" align="center">300 mg/d</th>
<th class="Rrule" align="center">600 mg/d</th>
<th class="Rrule" align="center">All PGB<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">[N=84]<br>%</th>
<th class="Rrule" align="center">[N=302]<br>%</th>
<th class="Rrule" align="center">[N=312]<br>%</th>
<th class="Rrule" align="center">[N=154]<br>%</th>
<th class="Rrule" align="center">[N=852]<br>%</th>
<th class="Rrule" align="center">[N=398]<br>%</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>PGB: pregabalin</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span> primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span>.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Investigator term; summary level term is <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Body as a whole</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Digestive system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Metabolic and <br>nutritional disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Musculoskeletal system</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Myasthenia</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Nervous system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Speech disorder</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory system</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Special senses</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurry vision</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorder</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Urogenital System</span></td></tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary Incontinence</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Underline">Controlled Add-On Studies in Adjunctive Therapy for Adult Patients with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5.1"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Leading to Discontinuation</span></p>
<p>Approximately 15% of patients receiving LYRICA and 6% of patients receiving placebo in add-on <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials discontinued prematurely due to adverse reactions. In the LYRICA treatment group, the adverse reactions most frequently leading to discontinuation were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (6%), <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (4%), and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3%). In comparison, &lt;1% of patients in the placebo group withdrew due to each of these events. Other adverse reactions that led to discontinuation of at least 1% of patients in the LYRICA group and at least twice as frequently compared to the placebo group were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (which each led to withdrawal in 2% or less of patients).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5.2"></a><p></p>
<p class="First"><span class="Italics">Most Common Adverse Reactions</span></p>
<p>Table 5 lists all dose-related adverse reactions occurring in at least 2% of all LYRICA-treated patients. Dose-relatedness was defined as the incidence of the adverse event in the 600 mg/day group was at least 2% greater than the rate in both the placebo and 150 mg/day groups. In these studies, 758 patients received LYRICA and 294 patients received placebo for up to 12 weeks. Because patients were also treated with 1 to 3 other AEDs, it is not possible to determine whether the following adverse reactions can be ascribed to LYRICA alone, or the combination of LYRICA and other AEDs. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of "mild" or "moderate".</p>
<table width="85%">
<caption><span>Table 5. Dose-related treatment-emergent adverse reaction incidence in controlled trials in adjunctive therapy for adult patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (events in at least 2% of all LYRICA-treated patients and the adverse reaction in the 600 mg/day group was ≥2% the rate in both the placebo and 150 mg/day groups)</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="left" valign="middle">Body System<br>Preferred Term</th>
<th class="Rrule" align="center">150 mg/d<br><br>[N = 185]<br>%</th>
<th class="Rrule" align="center">300 mg/d<br><br>[N = 90]<br>%</th>
<th class="Rrule" align="center">600 mg/d<br><br>[N = 395]<br>%</th>
<th class="Rrule" align="center">All PGB<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a><br><br>[N = 670]<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a><br>%</th>
<th class="Rrule" align="center">Placebo<br><br>[N = 294]<br>%</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>PGB: pregabalin</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Excludes patients who received the 50 mg dose in Study E1.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span> primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span>.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>Investigator term; summary level term is <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Body as a Whole</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Digestive System</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased Appetite</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="5"><span class="Bold">Metabolic and Nutritional Disorders</span></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Nervous System</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking Abnormal</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Speech Disorder</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal Gait</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">Twitching</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Special Senses</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a>
</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal Vision</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Underline">Controlled Studies with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.1"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Leading to Discontinuation</span></p>
<p>In clinical trials of patients with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>, 19% of patients treated with pregabalin (150–600 mg/day) and 10% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (6%) and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3%). In comparison, &lt;1% of placebo-treated patients withdrew due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin treatment group than in the placebo treatment group, were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>. Each of these adverse reactions led to withdrawal in approximately 1% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.2"></a><p></p>
<p class="First"><span class="Italics">Most Common Adverse Reactions</span></p>
<p>Table 6 lists all adverse reactions, regardless of causality, occurring in ≥2% of patients with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> in the 'all pregabalin' treatment group for which the incidence was greater than in the placebo treatment group. A majority of pregabalin-treated patients in clinical studies experienced adverse reactions with a maximum intensity of "mild" or "moderate".</p>
<a name="table6"></a><table width="85%">
<caption><span>Table 6. Treatment-emergent adverse reaction incidence in controlled trials in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (events) in at least 2% of all LYRICA-treated patients and occurring more frequently in the all pregabalin-group than in the placebo treatment group)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left">System Organ Class<br>Preferred term</th>
<th class="Rrule" align="center">150<br>mg/d</th>
<th class="Rrule" align="center">300<br>mg/d</th>
<th class="Rrule" align="center">450<br>mg/d</th>
<th class="Rrule" align="center">600<br>mg/d</th>
<th class="Rrule" align="center">All PGB<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">[N=132]<br>%</th>
<th class="Rrule" align="center">[N=502]<br>%</th>
<th class="Rrule" align="center">[N=505]<br>%</th>
<th class="Rrule" align="center">[N=378]<br>%</th>
<th class="Rrule" align="center">[N=1517]<br>%</th>
<th class="Rrule" align="center">[N=505]<br>%</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>PGB: pregabalin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Ear and Labyrinth<br>Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Gastrointestinal <br>Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">General Disorders and <br>Administrative Site <br>Conditions</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">Feeling abnormal</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">Feeling drunk</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <br><span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Investigations</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Metabolism and<br>Nutrition Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Musculoskeletal and<br>Connective Tissue<br>Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Nervous System<br>Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Disturbance in attention</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">Balance disorder</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Coordination abnormal</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Psychiatric Disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoric Mood</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Respiratory, Thoracic<br>and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Underline">Controlled Studies in <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">Spinal Cord Injury</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7.1"></a><p></p>
<p class="First"><span class="Italics">Adverse Reactions Leading to Discontinuation</span></p>
<p>In clinical trials of patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span>, 13% of patients treated with pregabalin and 10% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3%) and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (2%). In comparison, none of the placebo-treated patients withdrew due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin treatment group than in the placebo treatment group, were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>. Each of these adverse reactions led to withdrawal in less than 2% of patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7.2"></a><p></p>
<p class="First"><span class="Italics">Most Common Adverse Reactions</span></p>
<p>Table 7 lists all adverse reactions, regardless of causality, occurring in ≥2% of patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span> in the controlled trials. A majority of pregabalin-treated patients in clinical studies experienced adverse reactions with a maximum intensity of "mild" or "moderate".</p>
<a name="table7"></a><table width="75%">
<caption><span>Table 7. Treatment-emergent adverse reaction incidence in controlled trials in <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span> (events in at least 2% of all LYRICA-treated patients and occurring more frequently in the all pregabalin-group than in the placebo treatment group)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">System Organ Class<br>Preferred term</th>
<th class="Rrule" align="center">PGB<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> (N=182)</th>
<th class="Rrule" align="center">Placebo (N=174)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>PGB: Pregabalin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Ear and labryrinth disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Rrule" align="center">6.6</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Rrule" align="center">11.0</td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">8.2</td>
<td class="Rrule" align="center">5.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">4.9</td>
<td class="Rrule" align="center">4.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">General disorders and<br>administration site conditions</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">11.0</td>
<td class="Rrule" align="center">4.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">10.4</td>
<td class="Rrule" align="center">5.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">8.2</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">3.3</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">8.2</td>
<td class="Rrule" align="center">4.6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Investigations</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td class="Rrule" align="center">3.3</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">Blood creatine phosphokinase</span> increased</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Musculoskeletal and<br><span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular weakness</span></td>
<td class="Rrule" align="center">4.9</td>
<td class="Rrule" align="center">1.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Rrule" align="center">3.3</td>
<td class="Rrule" align="center">2.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">1.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">Joint swelling</span></td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="center">35.7</td>
<td class="Rrule" align="center">11.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">20.9</td>
<td class="Rrule" align="center">6.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Disturbance in attention</span></td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span></td>
<td class="Rrule" align="center">3.3</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Psychiatric disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">2.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoric mood</span></td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Renal and urinary disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Skin and subcutaneous tissue disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">Decubitus ulcer</span></td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">2.2</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.8"></a><p></p>
<p class="First"><span class="Underline">Other Adverse Reactions Observed During the Clinical Studies of LYRICA </span></p>
<p>Following is a list of treatment-emergent adverse reactions reported by patients treated with LYRICA during all clinical trials. The listing does not include those events already listed in the previous tables or elsewhere in labeling, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening.</p>
<p>Events are categorized by body system and listed in order of decreasing frequency according to the following definitions: <span class="Italics">frequent</span> adverse reactions are those occurring on one or more occasions in at least 1/100 patients; <span class="Italics">infrequent</span> adverse reactions are those occurring in 1/100 to 1/1000 patients; <span class="Italics">rare</span> reactions are those occurring in fewer than 1/1000 patients. Events of major clinical importance are described in the <span class="Italics">Warnings and Precautions </span>section (5).</p>
<p>Body as a Whole – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">Neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity reaction</span>, <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span>, <span class="product-label-link" type="condition" conceptid="4163983" conceptname="Granuloma">Granuloma</span>, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">Hangover effect</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Intentional Injury</span>, <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal Fibrosis</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span></p>
<p>Cardiovascular System – <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="434337" conceptname="Retinal vascular disorder">Retinal vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4095285" conceptname="ST segment depression">ST Depressed</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular Fibrillation</span></p>
<p>Digestive System – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">Cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">Melena</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">Mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">Tongue edema</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">Aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">Esophageal Ulcer</span>, <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">Periodontal abscess</span></p>
<p>Hemic and Lymphatic System – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">Hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="133169" conceptname="Myelofibrosis">Myelofibrosis</span>, <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">Polycythemia</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> decreased, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span></p>
<p>Metabolic and Nutritional Disorders – <span class="Italics">Rare:</span> Glucose Tolerance Decreased, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Urate Crystalluria</span></p>
<p>Musculoskeletal System – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Myasthenia</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="437097" conceptname="Congenital anomaly of cartilage">Chondrodystrophy</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Generalized Spasm</span></p>
<p>Nervous System – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">Depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, Sedation, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">Twitching</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">Apathy</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Aphasia</span>, <span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">Circumoral paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">Hostility</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">Hyperalgesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">Hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">Libido increased</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span>, <span class="Italics">Rare:</span> Addiction, <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">Cerebellar syndrome</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">Cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">Delirium</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">Delusions</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">Dysautonomia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal syndrome</span>, Guillain-Barré syndrome, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypalgesia</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial hypertension</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic reaction</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">Paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuritis</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality disorder</span>, <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">Psychotic depression</span>, <span class="product-label-link" type="condition" conceptid="444434" conceptname="Schizophreniform disorder">Schizophrenic reaction</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">Torticollis</span>, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">Trismus</span></p>
<p>Respiratory System – <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">Atelectasis</span>, <span class="product-label-link" type="condition" conceptid="4165112" conceptname="Bronchiolitis">Bronchiolitis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">Laryngismus</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Lung edema</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">Lung fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawn</span></p>
<p>Skin and Appendages – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">Skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">Vesiculobullous rash</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4028560" conceptname="Lichenoid dermatitis">Lichenoid dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4166542" conceptname="Melanosis">Melanosis</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorder</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechial rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpuric rash</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">Pustular rash</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">Skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">Skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">Skin nodule</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">Subcutaneous nodule</span></p>
<p>Special senses – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">Abnormality of accommodation</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">Blepharitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eyes</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">Eye hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">Hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span>, <span class="product-label-link" type="condition" conceptid="372903" conceptname="Retinal edema">Retinal edema</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Taste loss</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="434374" conceptname="Anisocoria">Anisocoria</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Blindness</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">Corneal ulcer</span>, <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="374041" conceptname="External ophthalmoplegia">Extraocular palsy</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">Night blindness</span>, <span class="product-label-link" type="condition" conceptid="4052337" conceptname="Ophthalmoplegia">Ophthalmoplegia</span>, <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">Optic atrophy</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">Papilledema</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">Parosmia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">Ptosis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span></p>
<p>Urogenital System – <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">Anorgasmia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney calculus</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">Menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">Metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">Nephritis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">Urine abnormality</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute kidney failure</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">Balanitis</span>, Bladder Neoplasm, <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">Cervicitis</span>, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">Dyspareunia</span>, <span class="product-label-link" type="condition" conceptid="4150043" conceptname="Epididymitis">Epididymitis</span>, Female lactation, <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">Glomerulitis</span>, <span class="product-label-link" type="condition" conceptid="4207977" conceptname="Disorder of ovary">Ovarian disorder</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">Pyelonephritis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.9"></a><p></p>
<p class="First"><span class="Underline">Comparison of Gender and Race</span></p>
<p>The overall adverse event profile of pregabalin was similar between women and men. There are insufficient data to support a statement regarding the distribution of adverse experience reports by race.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of LYRICA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> – <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> – <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span> – <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">Breast Enlargement</span></p>
<p>In addition, there are post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>) when LYRICA was co-administered with medications that have the potential to produce <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, such as opioid analgesics. There are also post-marketing reports of <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> in patients taking pregabalin and other CNS depressant medications.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Since LYRICA is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (&lt;2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. <span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies showed that LYRICA is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> would also not be expected to occur between LYRICA and commonly used antiepileptic drugs <span class="Italics">[see<a href="#S12"> Clinical Pharmacology (12)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<p class="First"><span class="Italics">Pharmacodynamics</span></p>
<p>Multiple oral doses of LYRICA were co-administered with oxycodone, lorazepam, or ethanol. Although no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were seen, additive effects on cognitive and gross motor functioning were seen when LYRICA was co-administered with these drugs. No clinically important effects on respiration were seen.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C. Increased incidences of fetal structural abnormalities and other manifestations of developmental toxicity, including lethality, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, and nervous and reproductive system functional impairment, were observed in the offspring of rats and rabbits given pregabalin during pregnancy, at doses that produced plasma pregabalin exposures (AUC) ≥5 times human exposure at the maximum recommended dose (MRD) of 600 mg/day.</p>
<p>When pregnant rats were given pregabalin (500, 1250, or 2500 mg/kg) orally throughout the period of organogenesis, incidences of specific skull alterations attributed to abnormally advanced ossification (premature fusion of the jugal and nasal sutures) were increased at ≥1250 mg/kg, and incidences of skeletal variations and retarded ossification were increased at all doses. Fetal body weights were decreased at the highest dose. The low dose in this study was associated with a plasma exposure (AUC) approximately 17 times human exposure at the MRD of 600 mg/day. A no-effect dose for rat embryo-fetal developmental toxicity was not established.</p>
<p>When pregnant rabbits were given LYRICA (250, 500, or 1250 mg/kg) orally throughout the period of organogenesis, decreased fetal body weight and increased incidences of skeletal malformations, visceral variations, and retarded ossification were observed at the highest dose. The no-effect dose for developmental toxicity in rabbits (500 mg/kg) was associated with a plasma exposure approximately 16 times human exposure at the MRD.</p>
<p>In a study in which female rats were dosed with LYRICA (50, 100, 250, 1250, or 2500 mg/kg) throughout gestation and lactation, offspring growth was reduced at ≥ 100 mg/kg and offspring survival was decreased at ≥250 mg/kg. The effect on offspring survival was pronounced at doses ≥1250 mg/kg, with 100% mortality in high-dose litters. When offspring were tested as adults, neurobehavioral abnormalities (decreased auditory startle responding) were observed at ≥250 mg/kg and reproductive impairment (decreased fertility and litter size) was seen at 1250 mg/kg. The no-effect dose for pre- and postnatal developmental toxicity in rats (50 mg/kg) produced a plasma exposure approximately 2 times human exposure at the MRD.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Use LYRICA during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>To provide information regarding the effects of in utero exposure to LYRICA, physicians are advised to recommend that pregnant patients taking LYRICA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effects of LYRICA on labor and delivery in pregnant women are unknown. In the prenatal-postnatal study in rats, pregabalin prolonged gestation and induced dystocia at exposures ≥50 times the mean human exposure (AUC<span class="Sub"> (0–24)</span> of 123 µg∙hr/mL) at the maximum recommended clinical dose of 600 mg/day.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if pregabalin is excreted in human milk; it is, however, present in the milk of rats. Because many drugs are excreted in human milk, and because of the potential for tumorigenicity shown for pregabalin in animal studies, decide whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of pregabalin in pediatric patients have not been established.</p>
<p>In studies in which pregabalin (50 to 500 mg/kg) was orally administered to young rats from early in the postnatal period (Postnatal Day 7) through sexual maturity, neurobehavioral abnormalities (deficits in learning and memory, altered locomotor activity, decreased auditory startle responding and <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span>) and reproductive impairment (delayed sexual maturation and decreased fertility in males and females) were observed at doses ≥50 mg/kg. The neurobehavioral changes of acoustic startle persisted at ≥250 mg/kg and locomotor activity and water maze performance at ≥500 mg/kg in animals tested after cessation of dosing and, thus, were considered to represent long-term effects. The low effect dose for developmental <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> and reproductive impairment in juvenile rats (50 mg/kg) was associated with a plasma pregabalin exposure (AUC) approximately equal to human exposure at the maximum recommended dose of 600 mg/day. A no-effect dose was not established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In controlled clinical studies of LYRICA in <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span>, 246 patients were 65 to 74 years of age, and 73 patients were 75 years of age or older.</p>
<p>In controlled clinical studies of LYRICA in <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, 282 patients were 65 to 74 years of age, and 379 patients were 75 years of age or older.</p>
<p>In controlled clinical studies of LYRICA in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, there were only 10 patients 65 to 74 years of age, and 2 patients who were 75 years of age or older.</p>
<p>No overall differences in safety and efficacy were observed between these patients and younger patients.</p>
<p>In controlled clinical studies of LYRICA in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span>, 106 patients were 65 years of age or older. Although the adverse reaction profile was similar between the two age groups, the following neurological adverse reactions were more frequent in patients 65 years of age or older: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">coordination abnormal</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.</p>
<p>LYRICA is known to be substantially excreted by the kidney, and the risk of toxic reactions to LYRICA may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because LYRICA is eliminated primarily by renal excretion, adjust the dose for elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see<a href="#S2.6"> Dosage and Administration (2.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">LYRICA is a Schedule V controlled substance.</p>
<p>LYRICA is not known to be active at receptor sites associated with drugs of abuse. As with any CNS active drug, carefully evaluate patients for history of drug abuse and observe them for signs of LYRICA misuse or abuse (e.g., development of tolerance, dose escalation, drug-seeking behavior).</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">In a study of recreational users (N=15) of sedative/hypnotic drugs, including alcohol, LYRICA (450 mg, single dose) received subjective ratings of "good drug effect," "high" and "liking" to a degree that was similar to diazepam (30 mg, single dose). In controlled clinical studies in over 5500 patients, 4 % of LYRICA-treated patients and 1 % of placebo-treated patients overall reported <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> as an adverse reaction, though in some patient populations studied, this reporting rate was higher and ranged from 1 to 12%.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">In clinical studies, following abrupt or rapid discontinuation of LYRICA, some patients reported symptoms including <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <span class="Italics">[see<a href="#S5.8"> Warnings and Precautions (5.8)</a>]</span>, consistent with physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. In the postmarketing experience, in addition to these reported symptoms there have also been reported cases of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<p class="First"><span class="Underline">Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans</span></p>
<p>There is limited experience with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of LYRICA. The highest reported accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of LYRICA during the clinical development program was 8000 mg, and there were no notable clinical consequences. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<p class="First"><span class="Underline">Treatment or Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with LYRICA. If indicated, elimination of unabsorbed drug may be attempted by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage; observe usual precautions to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. Contact a Certified Poison Control Center for up-to-date information on the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with LYRICA.</p>
<p>Although hemodialysis has not been performed in the few known cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it may be indicated by the patient's clinical state or in patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Standard hemodialysis procedures result in significant clearance of pregabalin (approximately 50% in 4 hours).</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Pregabalin is described chemically as (<span class="Italics">S</span>)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C<span class="Sub">8</span>H<span class="Sub">17</span>NO<span class="Sub">2</span> and the molecular weight is 159.23. The chemical structure of pregabalin is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-02.jpg"></div>
<p>Pregabalin is a white to off-white, crystalline solid with a pK<span class="Sub">a1</span> of 4.2 and a pK<span class="Sub">a2</span> of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35.</p>
<p>LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide.</p>
<p>LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">LYRICA (pregabalin) binds with high affinity to the alpha<span class="Sub">2</span>-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha<span class="Sub">2</span>-delta subunit may be involved in pregabalin's anti-nociceptive and antiseizure effects in animals. In animal models of <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, pregabalin has been shown to reduce calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord, possibly by disrupting alpha<span class="Sub">2</span>-delta containing-calcium channel trafficking and/or reducing calcium currents. Evidence from other animal models of <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and persistent <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> suggest the anti-nociceptive activities of pregabalin may also be mediated through interactions with descending noradrenergic and serotonergic pathways originating from the brainstem that modulate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> transmission in the spinal cord.</p>
<p>While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA<span class="Sub">A</span>, GABA<span class="Sub">B</span>, or benzodiazepine receptors, does not augment GABA<span class="Sub">A</span> responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport. Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Pregabalin is well absorbed after oral administration, is eliminated largely by renal excretion, and has an elimination half-life of about 6 hours.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Underline">Absorption and Distribution</span></p>
<p>Following oral administration of LYRICA capsules under fasting conditions, peak plasma concentrations occur within 1.5 hours. Pregabalin oral bioavailability is ≥90% and is independent of dose. Following single- (25 to 300 mg) and multiple- dose (75 to 900 mg/day) administration, maximum plasma concentrations (C<span class="Sub">max</span>) and area under the plasma concentration-time curve (AUC) values increase linearly. Following repeated administration, steady state is achieved within 24 to 48 hours. Multiple-dose pharmacokinetics can be predicted from single-dose data.</p>
<p>The rate of pregabalin absorption is decreased when given with food, resulting in a decrease in C<span class="Sub">max</span> of approximately 25% to 30% and an increase in T<span class="Sub">max</span> to approximately 3 hours. However, administration of pregabalin with food has no clinically relevant effect on the total absorption of pregabalin. Therefore, pregabalin can be taken with or without food.</p>
<p>Pregabalin does not bind to plasma proteins. The apparent volume of distribution of pregabalin following oral administration is approximately 0.5 L/kg. Pregabalin is a substrate for system L transporter which is responsible for the transport of large amino acids across the blood brain barrier. Although there are no data in humans, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. In addition, pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.2"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination</span></p>
<p>Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabeled pregabalin, approximately 90% of the administered dose was recovered in the urine as unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, pregabalin (S-enantiomer) did not undergo racemization to the R-enantiomer in mice, rats, rabbits, or monkeys.</p>
<p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug with a mean elimination half-life of 6.3 hours in subjects with normal renal function. Mean renal clearance was estimated to be 67.0 to 80.9 mL/min in young healthy subjects. Because pregabalin is not bound to plasma proteins this clearance rate indicates that renal tubular reabsorption is involved. Pregabalin elimination is nearly proportional to creatinine clearance (CLcr)<span class="Italics"> [see<a href="#S2.6">  Dosage and Administration, (2.6)</a>]</span>. 										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics in Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.1"></a><p></p>
<p class="First"><span class="Underline">Race</span></p>
<p>In population pharmacokinetic analyses of the clinical studies in various populations, the pharmacokinetics of LYRICA were not significantly affected by race (Caucasians, Blacks, and Hispanics).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.2"></a><p></p>
<p class="First"><span class="Underline">Gender</span></p>
<p>Population pharmacokinetic analyses of the clinical studies showed that the relationship between daily dose and LYRICA drug exposure is similar between genders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> and Hemodialysis</span></p>
<p>Pregabalin clearance is nearly proportional to creatinine clearance (CLcr). Dosage reduction in patients with renal dysfunction is necessary. Pregabalin is effectively removed from plasma by hemodialysis. Following a 4-hour hemodialysis treatment, plasma pregabalin concentrations are reduced by approximately 50%. For patients on hemodialysis, dosing must be modified [<span class="Italics">see<a href="#S2.6"> Dosage and Administration (2.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.4"></a><p></p>
<p class="First"><span class="Underline">Elderly</span></p>
<p>Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in CLcr. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function [<span class="Italics">see<a href="#S2.6"> Dosage and Administration, (2.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.5"></a><p></p>
<p class="First"><span class="Underline">Pediatric Pharmacokinetics</span></p>
<p>Pharmacokinetics of pregabalin have not been adequately studied in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.6"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.6.1"></a><p></p>
<p class="First"><span class="Italics">In Vitro Studies</span></p>
<p>Pregabalin, at concentrations that were, in general, 10-times those attained in clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 enzyme systems. In vitro drug interaction studies demonstrate that pregabalin does not induce CYP1A2 or CYP3A4 activity. Therefore, an increase in the metabolism of coadministered CYP1A2 substrates (e.g. theophylline, caffeine) or CYP 3A4 substrates (e.g., midazolam, testosterone) is not anticipated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.6.2"></a><p></p>
<h5></h5>
<p class="First"><span class="Italics">In Vivo Studies</span></p>
<p>The drug interaction studies described in this section were conducted in healthy adults, and across various patient populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.7"></a><p></p>
<p class="First"><span class="Underline">Gabapentin</span></p>
<p>The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> of pregabalin and gabapentin were investigated in 12 healthy subjects following concomitant single-dose administration of 100-mg pregabalin and 300-mg gabapentin and in 18 healthy subjects following concomitant multiple-dose administration of 200-mg pregabalin every 8 hours and 400-mg gabapentin every 8 hours. Gabapentin pharmacokinetics following single- and multiple-dose administration were unaltered by pregabalin coadministration. The extent of pregabalin absorption was unaffected by gabapentin coadministration, although there was a small reduction in rate of absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.8"></a><p></p>
<p class="First"><span class="Underline">Oral Contraceptive</span></p>
<p>Pregabalin coadministration (200 mg three times a day) had no effect on the steady-state pharmacokinetics of norethindrone and ethinyl estradiol (1 mg/35 µg, respectively) in healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.9"></a><p></p>
<p class="First"><span class="Underline">Lorazepam</span></p>
<p>Multiple-dose administration of pregabalin (300 mg twice a day) in healthy subjects had no effect on the rate and extent of lorazepam single-dose pharmacokinetics and single-dose administration of lorazepam (1 mg) had no effect on the steady-state pharmacokinetics of pregabalin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.10"></a><p></p>
<p class="First"><span class="Underline">Oxycodone</span></p>
<p>Multiple-dose administration of pregabalin (300 mg twice a day) in healthy subjects had no effect on the rate and extent of oxycodone single-dose pharmacokinetics. Single-dose administration of oxycodone (10 mg) had no effect on the steady-state pharmacokinetics of pregabalin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.11"></a><p></p>
<p class="First"><span class="Underline">Ethanol</span></p>
<p>Multiple-dose administration of pregabalin (300 mg twice a day) in healthy subjects had no effect on the rate and extent of ethanol single-dose pharmacokinetics and single-dose administration of ethanol (0.7 g/kg) had no effect on the steady-state pharmacokinetics of pregabalin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2.3.12"></a><p></p>
<p class="First"><span class="Underline">Phenytoin, carbamazepine, valproic acid, and lamotrigine</span></p>
<p>Steady-state trough plasma concentrations of phenytoin, carbamazepine and carbamazepine 10,11 epoxide, valproic acid, and lamotrigine were not affected by concomitant pregabalin (200 mg three times a day) administration.</p>
<p>Population pharmacokinetic analyses in patients treated with pregabalin and various concomitant medications suggest the following:</p>
<table width="75%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<thead><tr class="First Last">
<th align="left">Therapeutic  class</th>
<th align="left">Specific  concomitant drug studied</th>
</tr></thead>
<tbody>
<tr class="Botrule First"><td align="left" colspan="2"><span class="Bold Italics">Concomitant drug has no effect on the pharmacokinetics of pregabalin</span></td></tr>
<tr>
<td align="left">Hypoglycemics</td>
<td align="left">Glyburide, insulin, metformin</td>
</tr>
<tr class="Botrule">
<td align="left">Diuretics</td>
<td align="left">Furosemide</td>
</tr>
<tr class="Botrule">
<td align="left">Antiepileptic Drugs</td>
<td align="left">Tiagabine</td>
</tr>
<tr class="Botrule"><td align="left" colspan="2"><span class="Bold Italics">Concomitant drug has no effect on the pharmacokinetics of pregabalin and pregabalin has no effect on the pharmacokinetics of concomitant drug</span></td></tr>
<tr class="Last">
<td align="left">Antiepileptic Drugs</td>
<td align="left">Carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproic acid</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>A dose-dependent increase in the incidence of malignant vascular tumors (<span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span>) was observed in two <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mice (B6C3F1 and CD-1) given pregabalin (200, 1000, or 5000 mg/kg) in the diet for two years. Plasma pregabalin exposure (AUC) in mice receiving the lowest dose that increased <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span> was approximately equal to the human exposure at the maximum recommended dose (MRD) of 600 mg/day. A no-effect dose for induction of <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span> in mice was not established. No evidence of carcinogenicity was seen in two studies in Wistar rats following dietary administration of pregabalin for two years at doses (50, 150, or 450 mg/kg in males and 100, 300, or 900 mg/kg in females) that were associated with plasma exposures in males and females up to approximately 14 and 24 times, respectively, human exposure at the MRD.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Pregabalin was not mutagenic in bacteria or in mammalian cells <span class="Italics">in vitro</span>, was not clastogenic in mammalian systems <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>, and did not induce unscheduled DNA synthesis in mouse or rat hepatocytes.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>In fertility studies in which male rats were orally administered pregabalin (50 to 2500 mg/kg) prior to and during mating with untreated females, a number of adverse reproductive and developmental effects were observed. These included decreased sperm counts and sperm motility, increased sperm abnormalities, reduced fertility, increased preimplantation embryo loss, decreased litter size, decreased fetal body weights, and an increased incidence of fetal abnormalities. Effects on sperm and fertility parameters were reversible in studies of this duration (3–4 months). The no-effect dose for male reproductive toxicity in these studies (100 mg/kg) was associated with a plasma pregabalin exposure (AUC) approximately 3 times human exposure at the maximum recommended dose (MRD) of 600 mg/day.</p>
<p>In addition, adverse reactions on reproductive organ (testes, epididymides) histopathology were observed in male rats exposed to pregabalin (500 to 1250 mg/kg) in general toxicology studies of four weeks or greater duration. The no-effect dose for male reproductive organ histopathology in rats (250 mg/kg) was associated with a plasma exposure approximately 8 times human exposure at the MRD.</p>
<p>In a fertility study in which female rats were given pregabalin (500, 1250, or 2500 mg/kg) orally prior to and during mating and early gestation, disrupted estrous cyclicity and an increased number of days to mating were seen at all doses, and embryolethality occurred at the highest dose. The low dose in this study produced a plasma exposure approximately 9 times that in humans receiving the MRD. A no-effect dose for female reproductive toxicity in rats was not established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.4"></a><p></p>
<p class="First"><span class="Underline">Human Data</span></p>
<p>In a double-blind, placebo-controlled clinical trial to assess the effect of pregabalin on sperm motility, 30 healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment (one complete sperm cycle), the difference between placebo- and pregabalin-treated subjects in mean percent sperm with normal motility was &lt;4% and neither group had a mean change from baseline of more than 2%. Effects on other male reproductive parameters in humans have not been adequately studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Underline">Dermatopathy</span></p>
<p><span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesions</span> ranging from <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> to <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> were seen in repeated-dose toxicology studies in both rats and monkeys. The etiology of these <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> is unknown. At the maximum recommended human dose (MRD) of 600 mg/day, there is a 2-fold safety margin for the dermatological lesions. The more severe dermatopathies involving <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> were associated with pregabalin exposures (as expressed by plasma AUCs) of approximately 3 to 8 times those achieved in humans given the MRD. No increase in incidence of <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> was observed in clinical studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Underline">Ocular Lesions</span></p>
<p>Ocular lesions (characterized by <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal atrophy</span> [including loss of photoreceptor cells] and/or corneal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>/mineralization) were observed in two lifetime carcinogenicity studies in Wistar rats. These findings were observed at plasma pregabalin exposures (AUC) ≥2 times those achieved in humans given the maximum recommended dose of 600 mg/day. A no-effect dose for ocular lesions was not established. Similar lesions were not observed in lifetime carcinogenicity studies in two <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mice or in monkeys treated for 1 year.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">Diabetic Peripheral Neuropathy</span></h2>
<p class="First">The efficacy of the maximum recommended dose of LYRICA for the management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic peripheral neuropathy</span> was established in three double-blind, placebo-controlled, multicenter studies with three times a day dosing, two of which studied the maximum recommended dose. Patients were enrolled with either Type 1 or Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and a diagnosis of painful distal symmetrical sensorimotor <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> for 1 to 5 years. A total of 89% of patients completed Studies DPN 1 and DPN 2. The patients had a minimum mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥4 on an 11-point numerical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale ranging from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (worst possible <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>). The baseline mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores across the two studies ranged from 6.1 to 6.7. Patients were permitted up to 4 grams of acetaminophen per day as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, in addition to pregabalin. Patients recorded their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> daily in a diary.</p>
<p><span class="Italics">Study DPN 1:</span> This 5-week study compared LYRICA 25, 100, or 200 mg three times a day with placebo. Treatment with LYRICA 100 and 200 mg three times a day statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score and increased the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. There was no evidence of a greater effect on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores of the 200 mg three times a day dose than the 100 mg three times a day dose, but there was evidence of dose dependent adverse reactions <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>. For a range of levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to study endpoint, Figure 1 shows the fraction of patients achieving that level of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 1:</span> Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity – Study DPN 1</p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-03.jpg"></div>
<p><span class="Italics">Study DPN 2:</span> This 8-week study compared LYRICA 100 mg three times a day with placebo. Treatment with LYRICA 100 mg three times a day statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score and increased the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. For various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to study endpoint, Figure 2 shows the fraction of patients achieving that level of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 2:</span> Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity– Study DPN 2</p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<h2>14.2 Postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></h2>
<p class="First">The efficacy of LYRICA for the management of postherpetic <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> was established in three double-blind, placebo-controlled, multicenter studies. These studies enrolled patients with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span> persisting for at least 3 months following healing of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and a minimum baseline score of ≥4 on an 11-point numerical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale ranging from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (worst possible <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>). Seventy-three percent of patients completed the studies. The baseline mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores across the 3 studies ranged from 6 to 7. Patients were permitted up to 4 grams of acetaminophen per day as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, in addition to pregabalin. Patients recorded their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> daily in a diary.</p>
<p><span class="Italics">Study PHN 1:</span> This 13-week study compared LYRICA 75, 150, and 300 mg twice daily with placebo. Patients with creatinine clearance (CLcr) between 30 to 60 mL/min were randomized to 75 mg, 150 mg, or placebo twice daily. Patients with creatinine clearance greater than 60 mL/min were randomized to 75 mg, 150 mg, 300 mg or placebo twice daily. In patients with creatinine clearance greater than 60 mL/min treatment with all doses of LYRICA statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score and increased the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. Despite differences in dosing based on renal function, patients with creatinine clearance between 30 to 60 mL/min tolerated LYRICA less well than patients with creatinine clearance greater than 60 mL/min as evidenced by higher rates of discontinuation due to adverse reactions. For various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to study endpoint, Figure 3 shows the fraction of patients achieving that level of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 3:</span> Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity– Study PHN 1</p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-05.jpg"></div>
<p><span class="Italics">Study PHN 2:</span> This 8-week study compared LYRICA 100 or 200 mg three times a day with placebo, with doses assigned based on creatinine clearance. Patients with creatinine clearance between 30 to 60 mL/min were treated with 100 mg three times a day, and patients with creatinine clearance greater than 60 mL/min were treated with 200 mg three times daily. Treatment with LYRICA statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score and increased the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. For various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to study endpoint, Figure 4 shows the fraction of patients achieving those levels of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 4:</span> Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity – Study PHN 2</p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-06.jpg"></div>
<p><span class="Italics">Study PHN 3:</span> This 8-week study compared LYRICA 50 or 100 mg three times a day with placebo with doses assigned regardless of creatinine clearance. Treatment with LYRICA 50 and 100 mg three times a day statistically significantly improved the endpoint mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score and increased the proportion of patients with at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. Patients with creatinine clearance between 30 to 60 mL/min tolerated LYRICA less well than patients with creatinine clearance greater than 60 mL/min as evidenced by markedly higher rates of discontinuation due to adverse reactions. For various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to study endpoint, Figure 5 shows the fraction of patients achieving that level of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 5:</span> Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity– Study PHN 3</p>
<div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.3"></a><p></p>
<h2>14.3 Adjunctive Therapy for Adult Patients with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">The efficacy of LYRICA as adjunctive therapy in partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in three 12-week, randomized, double-blind, placebo-controlled, multicenter studies in adult patients. Patients were enrolled who had partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> with or without secondary generalization and were not adequately controlled with 1 to 3 concomitant antiepileptic drugs (AEDs). Patients taking gabapentin were required to discontinue gabapentin treatment 1 week prior to entering baseline. During an 8-week baseline period, patients had to experience at least 6 partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> with no <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-free period exceeding 4 weeks. The mean duration of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> was 25 years in these 3 studies and the mean and median baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequencies were 22.5 and 10 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per month, respectively. Approximately half of the patients were taking 2 concurrent AEDs at baseline. Among the LYRICA-treated patients, 80% completed the double-blind phase of the studies.</p>
<p>Table 8 shows median baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates and median percent reduction in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency by dose.</p>
<table width="75%">
<caption><span>Table 8. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Response in Controlled, Add-On <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Studies</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="5%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Daily Dose of Pregabalin</th>
<th class="Rrule" align="center">Dosing Regimen</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">Baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency/mo</th>
<th class="Rrule" align="center">Median % Change from Baseline</th>
<th class="Rrule" align="center">p-value, vs. placebo</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Study E1</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Placebo</td>
<td class="Rrule" align="center">BID</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">9.5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">50 mg/day</td>
<td class="Rrule" align="center">BID</td>
<td class="Rrule" align="center">88</td>
<td class="Rrule" align="center">10.3</td>
<td class="Rrule" align="center">-9</td>
<td class="Rrule" align="center">0.4230</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">150 mg/day</td>
<td class="Rrule" align="center">BID</td>
<td class="Rrule" align="center">86</td>
<td class="Rrule" align="center">8.8</td>
<td class="Rrule" align="center">-35</td>
<td class="Rrule" align="center">0.0001</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">300 mg/day</td>
<td class="Rrule" align="center">BID</td>
<td class="Rrule" align="center">90</td>
<td class="Rrule" align="center">9.8</td>
<td class="Rrule" align="center">-37</td>
<td class="Rrule" align="center">0.0001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">600 mg/day</td>
<td class="Rrule" align="center">BID</td>
<td class="Rrule" align="center">89</td>
<td class="Rrule" align="center">9.0</td>
<td class="Rrule" align="center">-51</td>
<td class="Rrule" align="center">0.0001</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Study E2</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Placebo</td>
<td class="Rrule" align="center">TID</td>
<td class="Rrule" align="center">96</td>
<td class="Rrule" align="center">9.3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">150 mg/day</td>
<td class="Rrule" align="center">TID</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">11.5</td>
<td class="Rrule" align="center">-17</td>
<td class="Rrule" align="center">0.0007</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">600 mg/day</td>
<td class="Rrule" align="center">TID</td>
<td class="Rrule" align="center">92</td>
<td class="Rrule" align="center">12.3</td>
<td class="Rrule" align="center">-43</td>
<td class="Rrule" align="center">0.0001</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Study E3</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">Placebo</td>
<td class="Rrule" align="center">BID/TID</td>
<td class="Rrule" align="center">98</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">-1</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">600 mg/day</td>
<td class="Rrule" align="center">BID</td>
<td class="Rrule" align="center">103</td>
<td class="Rrule" align="center">9.5</td>
<td class="Rrule" align="center">-36</td>
<td class="Rrule" align="center">0.0001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">600 mg/day</td>
<td class="Rrule" align="center">TID</td>
<td class="Rrule" align="center">111</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">-48</td>
<td class="Rrule" align="center">0.0001</td>
</tr>
</tbody>
</table>
<p>In the first study (E1), there was evidence of a dose-response relationship for total daily doses of Lyrica between 150 and 600 mg/day; a dose of 50 mg/day was not effective. In the first study (E1), each daily dose was divided into two equal doses (twice a day dosing). In the second study (E2), each daily dose was divided into three equal doses (three times a day dosing). In the third study (E3), the same total daily dose was divided into two equal doses for one group (twice a day dosing) and three equal doses for another group (three times a day dosing). While the three times a day dosing group in Study E3 performed numerically better than the twice a day dosing group, this difference was small and not statistically significant.</p>
<p>A secondary outcome measure included the responder rate (proportion of patients with ≥50% reduction from baseline in partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency). The following figure displays responder rate by dose for two of the studies.</p>
<p><span class="Bold">Figure 6:</span> Responder rate by add-on <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> study</p>
<div class="Figure"><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-08.jpg"></div>
<p><span class="Bold">Figure 7:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Reduction by Dose (All Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>) for Studies E1, E2, and E3</p>
<div class="Figure"><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-09.jpg"></div>
<p>Subset evaluations of the antiseizure efficacy of LYRICA showed no clinically important differences as a function of age, gender, or race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.4"></a><p></p>
<h2>14.4 Management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> </h2>
<p class="First">The efficacy of LYRICA for management of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> was established in one 14-week, double-blind, placebo-controlled, multicenter study (F1) and one six-month, randomized withdrawal study (F2). Studies F1 and F2 enrolled patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> using the American College of Rheumatology (ACR) criteria (history of widespread <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> for 3 months, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> present at 11 or more of the 18 specific tender point sites). The studies showed a reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> by visual analog scale. In addition, improvement was demonstrated based on a patient global assessment (PGIC), and on the <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Impact Questionnaire (FIQ).</p>
<p><span class="Italics">Study F1</span>: This 14-week study compared LYRICA total daily doses of 300 mg, 450 mg and 600 mg with placebo. Patients were enrolled with a minimum mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of greater than or equal to 4 on an 11-point numeric <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale and a score of greater than or equal to 40 mm on the 100 mm <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> visual analog scale (VAS). The baseline mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score in this trial was 6.7. Responders to placebo in an initial one-week run-in phase were not randomized into subsequent phases of the study. A total of 64% of patients randomized to LYRICA completed the study. There was no evidence of a greater effect on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores of the 600 mg daily dose than the 450 mg daily dose, but there was evidence of dose-dependent adverse reactions [<span class="Italics">see<a href="#S6.1"> Adverse Reactions (6.1)</a></span>]. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study. The results are summarized in Figure 8 and Table 9.</p>
<p>For various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to study endpoint, Figure 8 shows the fraction of patients achieving that level of improvement. The figure is cumulative. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as Week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 8:</span> Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity – <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Study F1</p>
<div class="Figure"><img alt="Figure 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-10.jpg"></div>
<table width="75%">
<caption><span>Table 9. Patient Global Response in <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Study F1</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="3">Patient Global Impression of Change</th></tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center">Treatment Group<br>(mg/day)</th>
<th class="Rrule" align="center" valign="middle">% Any Improvement</th>
<th class="Rrule" align="center" valign="middle">95% CI</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">PGB = Pregabalin<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Placebo</td>
<td class="Rrule" align="center">47.6</td>
<td class="Rrule" align="center">(40.0,55.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PGB 300</td>
<td class="Rrule" align="center">68.1</td>
<td class="Rrule" align="center">(60.9, 75.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">PGB 450</td>
<td class="Rrule" align="center">77.8</td>
<td class="Rrule" align="center">(71.5, 84.0)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">PGB 600</td>
<td class="Rrule" align="center">66.1</td>
<td class="Rrule" align="center">(59.1, 73.1)</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Study F2</span>: This randomized withdrawal study compared LYRICA with placebo. Patients were titrated during a 6-week open-label dose optimization phase  to a total daily dose of 300 mg, 450 mg, or 600 mg. Patients were considered to be responders if they had both: 1) at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (VAS) and, 2) rated their overall improvement on the PGIC as "much improved" or "very much improved." Those who responded to treatment were then randomized in the double-blind treatment phase to either the dose achieved in the open-label phase or to placebo. Patients were treated for up to 6 months following randomization. Efficacy was assessed by time to loss of therapeutic response, defined as 1) less than 30% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (VAS) from open-label baseline during two consecutive visits of the double-blind phase, or 2) worsening of FM symptoms necessitating an alternative treatment. Fifty-four percent of patients were able to titrate to an effective and tolerable dose of LYRICA during the 6-week open-label phase. Of the patients entering the randomized treatment phase assigned to remain on LYRICA, 38% of patients completed 26 weeks of treatment versus 19% of placebo-treated patients.</p>
<p>When considering return of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or withdrawal due to adverse events as loss of response (LTR), treatment with LYRICA resulted in a longer time to loss of therapeutic response than treatment with placebo. Fifty-three percent of the pregabalin-treated subjects compared to 33% of placebo patients remained on study drug and maintained a therapeutic response to Week 26 of the study. Treatment with LYRICA also resulted in a longer time to loss of response based on the FIQ<a name="footnote-reference-15" href="#footnote-15" class="Sup">1</a>, and longer time to loss of overall assessment of patient status, as measured by the PGIC<a name="footnote-reference-16" href="#footnote-16" class="Sup">2</a>.</p>
<p><span class="Bold">Figure 9:</span> Time to Loss of Therapeutic Response, <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">Fibromyalgia</span> Study F2 (Kaplan-Meier Analysis)</p>
<div class="Figure"><img alt="Figure 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-11.jpg"></div>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">1</a></dt>
<dd>Time to worsening of the FIQ was defined as the time to a 1-point increase from double-blind baseline in each of the subscales, and a 5-point increase from double-blind baseline evaluation for the FIQ total score.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">2</a></dt>
<dd>Time to PGIC lack of improvement was defined as time to PGIC assessments indicating less improvement than "much improvement."</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.5"></a><p></p>
<h2>14.5 Management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuropathic Pain</span> Associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">Spinal Cord Injury</span></h2>
<p class="First">The efficacy of LYRICA for the management of <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span> was established in two double-blind, placebo-controlled, multicenter studies. Patients were enrolled with <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span> associated with <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span> that persisted continuously for at least three months or with relapses and remissions for at least six months. A total of 63% of patients completed study 1 and 84% completed study 2. The patients had a minimum mean baseline <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score of ≥4 on an 11-point numerical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale ranging from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 10 (worst possible <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>). The baseline mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores across the two studies ranged from 6.5 to 6.7.</p>
<p>Patients were allowed to take opioids, non-opioid analgesics, antiepileptic drugs, muscle relaxants, and antidepressant drugs if the dose was stable for 30 days prior to screening. Patients were allowed to take acetaminophen and nonsteroidal anti-inflammatory drugs during the studies.</p>
<p><span class="Italics">Study SCI 1</span>: This 12-week, randomized, double-blind, parallel-group, multicenter, flexible dose (150–600 mg/day) study compared pregabalin with placebo. The 12-week study consisted of a 3-week dose adjustment phase and a 9-week dose maintenance phase. Treatment with LYRICA 150–600 mg/day statistically significantly improved the endpoint weekly mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score, and increased the proportion of patients with at least a 30% and 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. The fraction of patients achieving various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to Week 12 is presented in Figure 10. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 10</span>: Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity – Study SCI 1</p>
<div class="Figure"><img alt="Figure 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-12.jpg"></div>
<p><span class="Italics">Study SCI 2</span>: This 16-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter, flexible dose (150–600 mg/day, in increments of 150 mg) study compared the efficacy, safety and tolerability of pregabalin with placebo. The 16-week study consisted of a 4-week dose adjustment phase and a 12-week dose maintenance phase. Treatment with LYRICA statistically significantly improved the endpoint weekly mean <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score, and increased the proportion of patients with at least a 30% and 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score from baseline. The fraction of patients achieving various levels of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity from baseline to Week 16 is presented in Figure 11. Some patients experienced a decrease in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as early as week 1, which persisted throughout the study.</p>
<p><span class="Bold">Figure 11</span>:  Patients Achieving Various Levels of Improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Intensity – Study SCI 2</p>
<div class="Figure"><img alt="Figure 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-13.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_HOWSUPPLIED"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table border="0" cellpadding="1" cellspacing="1">
<colgroup><col width="100%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" valign="bottom"><p class="First">Repackaged by A-S Medication Solutions - Libertyville, IL<br>See <span class="Bold Italics"><a href="#Repack">REPACKAGING INFORMATION</a></span> for available configurations.</p></td></tr>
<tr class="Last"><td align="left" valign="bottom"><img alt="A-S Medication Solutions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=ASMLogo.jpg"></td></tr>
</tbody>
</table>
<p class="First"><span class="Italics">25 mg capsules:</span></p>
<p>White, hard-gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 25" on the body; available in:</p>
<p>Bottles of 90:         NDC 0071-1012-68</p>
<p><span class="Italics">50 mg capsules:</span></p>
<p>White, hard-gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 50" and an ink band on the body, available in:</p>
<p>Bottles of 90:         NDC 0071-1013-68</p>
<p>Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packages of 100:       NDC 0071-1013-41</p>
<p><span class="Italics">75 mg capsules:</span></p>
<p>White/orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 75" on the body; available in:</p>
<p>Bottles of 90:        NDC 0071-1014-68</p>
<p>Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packages of 100:     NDC 0071-1014-41</p>
<p><span class="Italics">100 mg capsules:</span></p>
<p>Orange, hard-gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 100" on the body, available in:</p>
<p>Bottles of 90:       NDC 0071-1015-68</p>
<p>Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packages of 100:     NDC 0071-1015-41</p>
<p><span class="Italics">150 mg capsules:</span></p>
<p>White hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 150" on the body, available in:</p>
<p>Bottles of 90:       NDC 0071-1016-68</p>
<p>Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packages of 100:       NDC 0071-1016-41</p>
<p><span class="Italics">200 mg capsules:</span></p>
<p>Light orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 200" on the body, available in:</p>
<p>Bottles of 90:       NDC 0071-1017-68</p>
<p><span class="Italics">225 mg capsules:</span></p>
<p>White/light orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 225" on the body; available in:</p>
<p>Bottles of 90:       NDC 0071-1019-68</p>
<p><span class="Italics">300 mg capsules:</span></p>
<p>White/orange hard gelatin capsule printed with black ink "Pfizer" on the cap, "PGN 300" on the body, available in:</p>
<p>Bottles of 90:       NDC 0071-1018-68</p>
<p><span class="Italics">20 mg/mL oral solution:</span></p>
<p>16 fluid ounce white high density polyethylene (HDPE) bottle with a polyethylene-lined closure: </p>
<p>16 fluid ounce bottle            NDC 0071-1020-01</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Storage and Handling</p>
<p>Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).</p>
<p><span class="Bold">See<a href="#MG"> FDA-Approved Medication Guide</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1 Medication Guide</h2>
<p class="First">Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking LYRICA. Instruct patients to take LYRICA only as prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></h2>
<p class="First">Advise patients that LYRICA may cause <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth (lip, gum, tongue) and neck (larynx and pharynx) that can lead to life-threatening respiratory compromise. Instruct patients to discontinue LYRICA and immediately seek medical care if they experience these symptoms [<span class="Italics">see<a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Advise patients that LYRICA has been associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>. Instruct patients to discontinue LYRICA and immediately seek medical care if they experience these symptoms <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<h2>17.4 Suicidal Thinking and Behavior</h2>
<p class="First">Patients, their caregivers, and families should be counseled that AEDs, including LYRICA, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Report behaviors of concern immediately to healthcare providers <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">Counsel patients that LYRICA may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and other CNS signs and symptoms. Accordingly, advise patients not to drive, operate complex machinery, or engage in other hazardous activities until they have gained sufficient experience on LYRICA to gauge whether or not it affects their mental, visual, and/or motor performance adversely. <span class="Italics">[see<a href="#S5.6"> Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">Counsel patients that LYRICA may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Advise patients that concomitant treatment with LYRICA and a thiazolidinedione antidiabetic agent may lead to an additive effect on <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. For patients with preexisting cardiac conditions, this may increase the risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.<span class="Italics"> [see<a href="#S5.5"> Warnings and Precautions (5.5 </a>and<a href="#S5.7"> 5.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.7"></a><p></p>
<h2>17.7 Abrupt or Rapid Discontinuation</h2>
<p class="First">Advise patients to take LYRICA as prescribed. Abrupt or rapid discontinuation may result in <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="Italics">[see<a href="#S5.8"> Warnings and Precautions (5.8)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.8"></a><p></p>
<h2>17.8 Ophthalmological Effects</h2>
<p class="First">Counsel patients that LYRICA may cause <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. Inform patients that if changes in vision occur, they should notify their physician <span class="Italics">[see<a href="#S5.10"> Warnings and Precautions (5.10)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.9"></a><p></p>
<h2>17.9 Creatine Kinase Elevations</h2>
<p class="First">Instruct patients to promptly report unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="Italics">[see<a href="#S5.11"> Warnings and Precautions (5.11)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.10"></a><p></p>
<h2>17.10 CNS Depressants</h2>
<p class="First">Inform patients who require concomitant treatment with central nervous system depressants such as opiates or benzodiazepines that they may experience additive CNS side effects, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see<a href="#S5.6"> Warnings and Precautions (5.6) </a>and<a href="#S7"> Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.11"></a><p></p>
<h2>17.11 Alcohol</h2>
<p class="First">Tell patients to avoid consuming alcohol while taking LYRICA, as LYRICA may potentiate the impairment of motor skills and sedating effects of alcohol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.12"></a><p></p>
<h2>17.12 Use in Pregnancy</h2>
<p class="First">Instruct patients to notify their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breast feeding or intend to breast feed during therapy <span class="Italics">[see<a href="#S8.1"> Use In Specific Populations (8.1) </a>and<a href="#S8.3"> (8.3)</a>]</span>.</p>
<p>Encourage patients to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 <span class="Italics">[see<a href="#S8.1"> Use In Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.13"></a><p></p>
<h2>17.13 Male Fertility</h2>
<p class="First">Inform men being treated with LYRICA who plan to father a child of the potential risk of male-mediated <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. In preclinical studies in rats, pregabalin was associated with an increased risk of male-mediated <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. The clinical significance of this finding is uncertain <span class="Italics">[see<a href="#S13.1"> Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.14"></a><p></p>
<h2>17.14 Dermatopathy</h2>
<p class="First">Instruct diabetic patients to pay particular attention to skin integrity while being treated with LYRICA. Some animals treated with pregabalin developed <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcerations</span>, although no increased incidence of <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> associated with LYRICA was observed in clinical trials <span class="Italics">[see<a href="#S13.2"> Nonclinical Toxicology (13.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-14.jpg"></p>
<p>LAB-0294-23.0</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">LYRICA (LEER-i-kah)<br>(pregabalin)<br>Capsules and Oral Solution, CV</span></p>
<p>Read this Medication Guide before you start taking LYRICA and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. If you have any questions about LYRICA, ask your healthcare provider or pharmacist.</p>
<p><a name="mostimportant"></a><span class="Bold">What is the most important information I should know about LYRICA?</span></p>
<p><span class="Bold">LYRICA may cause serious side effects including:</span></p>
<ul class="Disc">
<li><span class="Bold">Serious, even life-threatening, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span></li>
<li><span class="Bold">Suicidal thoughts or actions</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of your hands, legs and feet</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></span></li>
</ul>
<p><span class="Bold">These serious side effects are described below:</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Serious, even life-threatening, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span><p class="First">Stop taking LYRICA and call your healthcare provider right away if you have any of these signs of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</p>
<ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, mouth, lips, gums, tongue, throat or neck</li>
<li>trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> (raised bumps) or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></li>
</ul>
</dd>
</dl>
<dl>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Like other antiepileptic drugs, LYRICA may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. </span><p class="First">Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</p>
<ul class="Square">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">If you have suicidal thoughts or actions, do not stop LYRICA without first talking to a healthcare provider.</span></p>
<ul class="Square">
<li>Stopping LYRICA suddenly can cause serious problems.</li>
<li>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.</li>
</ul>
<p><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions?</span></p>
<ul class="Square">
<li>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.</li>
<li>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.</li>
</ul>
</dd>
</dl>
<dl>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of your hands, legs and feet</span>. This <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> can be a serious problem for   people with heart problems.</dd>
</dl>
<dl>
<dt class="Bold">4.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>. </span><p class="First">Do not drive a car, work with machines, or do other dangerous activities until you know how LYRICA affects you. Ask your healthcare provider about when it will be okay to do these activities.</p>
</dd>
</dl>
<p><span class="Bold">What is LYRICA?</span></p>
<p>LYRICA is a prescription medicine used in adults, 18 years and older, to treat:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from damaged nerves (<span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span>) that happens with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from damaged nerves (<span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span>) that follows healing of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span></li>
<li><span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> when taken together with other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicines</li>
<li><span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> all over your body)</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from damaged nerves (<span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span>) that follows <span class="product-label-link" type="condition" conceptid="4235863" conceptname="Spinal cord injury">spinal cord injury</span></li>
</ul>
<p>LYRICA has not been studied in children under 18 years of age.</p>
<p><span class="Bold">Who Should Not Take LYRICA?</span></p>
<p><span class="Bold">Do not take LYRICA if you are allergic to pregabalin or any of the ingredients in LYRICA.</span></p>
<p>See "<a href="#mostimportant">What is the most important information I should know about LYRICA</a>?" for the signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>See the end of this leaflet for a complete list of ingredients in LYRICA.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking LYRICA?</span></p>
<p>Before taking LYRICA, tell your healthcare provider about all your medical conditions, including if you:</p>
<ul class="Disc">
<li>have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems or   suicidal thoughts or behavior</li>
<li>have kidney problems or get kidney dialysis</li>
<li>have heart problems including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></li>
<li>have a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problem or a low blood platelet count</li>
<li>have abused prescription medicines, street drugs, or alcohol in the past</li>
<li>have ever had <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, mouth, tongue, lips, gums, neck, or throat (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>)</li>
<li>plan to father a child. Animal studies have shown that pregabalin, the active ingredient in LYRICA, made male animals less fertile and caused sperm to change. Also, in animal studies, <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> were seen in the offspring (babies) of male animals treated with pregabalin. It is not known if these problems can happen in people who take LYRICA.</li>
<li>
<span class="Bold">are pregnant or plan to become pregnant. It is not known if LYRICA will harm your unborn baby.</span>   You and your healthcare provider will have to decide if you should take LYRICA while you are pregnant. If you become pregnant while taking LYRICA, talk to your healthcare provider   about registering with the North American Antiepileptic Drug Pregnancy   Registry. You can enroll in this registry by calling 1-888-233-2334.   The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.</li>
<li>
<span class="Bold">are breastfeeding. It is not known if LYRICA passes into breast milk and if it can harm your baby. </span>You and your healthcare provider should discuss whether you should take LYRICA or breast-feed, but you should not do both</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take including prescription and non-prescription medicines, vitamins or herbal supplements. LYRICA and other medicines may affect each other causing side effects. Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>angiotensin converting enzyme (ACE) inhibitors, which are used to treat many conditions, including high blood pressure. You   may have a higher chance for <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> if these medicines are   taken with LYRICA. See "<a href="#mostimportant">What is the most important information   I should know about LYRICA?</a>"</li>
<li>Avandia (rosiglitazone), Avandamet (contains rosiglitazone and metformin), or Actos (pioglitazone) for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. You may have a higher chance of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands or feet if these medicines are taken with LYRICA. See   "<a href="#sideeffects">What are the possible side effects of LYRICA.</a>"</li>
<li>any narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine (such as oxycodone), tranquilizers or medicines for <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (such as lorazepam). You may have a higher chance for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> if these medicines are taken with LYRICA.</li>
<li>any medicines that make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span></li>
</ul>
<p>Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without talking with your healthcare provider.</p>
<p><span class="Bold">How should I take LYRICA?</span></p>
<ul class="Disc">
<li>Take LYRICA exactly as prescribed. Your healthcare provider will tell you how much LYRICA to take and when to take it. Take LYRICA at the same times each day.</li>
<li>LYRICA may be taken with or without food.</li>
<li>Your healthcare provider may change your dose. Do not change your dose without talking to   your healthcare provider.</li>
<li>Do not stop taking LYRICA without talking to your healthcare provider. If you stop taking   LYRICA suddenly you may have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, trouble sleeping, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, or you may feel anxious. If you have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and you stop taking LYRICA suddenly, you may have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> more often. Talk with your healthcare provider about how to stop LYRICA slowly.</li>
<li>If you miss a dose,   take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. <span class="Bold">Do not take two doses at the same time. </span>
</li>
<li>If you take too much LYRICA, call your healthcare provider or poison control center, or go to the nearest emergency room right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking LYRICA?</span></p>
<ul class="Disc">
<li><span class="Bold">Do not drive a car, work with machines, or do other dangerous activities until you know how LYRICA affects you.</span></li>
<li>
<span class="Bold">Do not drink alcohol while taking LYRICA.</span> LYRICA and alcohol can affect each other and increase side effects such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</li>
</ul>
<p><a name="sideeffects"></a><span class="Bold">What are the possible side effects of LYRICA?</span></p>
<p>LYRICA may cause serious side effects, including:</p>
<ul class="Disc">
<li>See "<a href="#mostimportant">What is the most important information I should know about LYRICA</a>?"</li>
<li>
<span class="Bold">muscle problems, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, soreness, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></span>. If you have these symptoms,   especially if you feel sick and have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, tell your healthcare provider right away.</li>
<li>
<span class="Bold">problems with your eyesight, including <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurry vision</span>. </span>Call your healthcare provider if you have any changes in your eyesight.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. </span>If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> may affect the management of your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.   <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> can also be a serious problem for people with heart problems.</li>
<li><span class="Bold">feeling "high"  </span></li>
</ul>
<p><span class="Bold">The most common side effects of LYRICA are:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurry vision</span></li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li>
<li>trouble concentrating</li>
<li><span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">swelling of hands</span> and feet</li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
</ul>
<p>LYRICA caused skin sores in animal studies. Skin sores did not happen in studies in people. If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, you should pay attention to your skin while taking LYRICA and tell your healthcare provider about any sores or skin problems.</p>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of LYRICA. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store LYRICA?</span></p>
<ul class="Disc">
<li>Store LYRICA capsules and oral solution at room temperature, 59°F to 86°F (15°C to 30°C) in its original package.</li>
<li>Safely throw away any LYRICA that is out of date or no longer needed.</li>
<li><span class="Bold">Keep LYRICA and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General information about LYRICA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use LYRICA for a condition for which it was not prescribed. Do not give LYRICA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about LYRICA. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about LYRICA that is written for health professionals.</p>
<p>You can also visit the LYRICA website at www.LYRICA.com or call 1-866-459-7422 (1-866-4LYRICA).</p>
<p><span class="Bold">What are the ingredients In LYRICA?</span></p>
<p>Active ingredient: pregabalin</p>
<p>Inactive ingredients:</p>
<p><span class="Bold">LYRICA capsules: </span>lactose monohydrate, cornstarch, talc</p>
<p>Capsule shell: gelatin and titanium dioxide; Orange capsule shell: red iron oxide; White capsule shell: sodium lauryl sulfate, colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells.</p>
<p>Imprinting ink: shellac, black iron oxide, propylene glycol, potassium hydroxide.</p>
<p><span class="Bold">LYRICA oral solution:</span> methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=lyrica-14.jpg"></p>
<p>LAB-0299-12.0</p>
<p>12/2013</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Repack"></a><a name="section-20"></a><p></p>
<h1>REPACKAGING INFORMATION</h1>
<p class="First">Please reference the <span class="Bold Italics"><a href="#LINK_HOWSUPPLIED">HOW SUPPLIED</a></span> section listed above for a description of individual tablets or capsules.  This drug product has been received by A-S Medication Solutions - Libertyville, IL in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations.  The package configurations available from A-S Medication Solutions are listed below:</p>
<table border="0" cellpadding="1" cellspacing="1" width="46%">
<colgroup>
<col width="18%">
<col width="10%">
<col width="18%">
</colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Bold" align="center" valign="bottom">NDC#</td>
<td align="center" valign="bottom"><span class="Bold">Count</span></td>
<td align="center" valign="bottom"><span class="Bold">Strength</span></td>
</tr>
<tr>
<td align="center" valign="bottom">50090-1230-0</td>
<td align="center">60</td>
<td align="center">50 mg</td>
</tr>
<tr>
<td align="center" valign="bottom">50090-1230-0</td>
<td align="center">60</td>
<td align="center">50 mg</td>
</tr>
<tr>
<td align="center" valign="bottom">50090-1230-1</td>
<td align="center">90</td>
<td align="center">50 mg</td>
</tr>
<tr>
<td align="center" valign="bottom">50090-1230-1</td>
<td align="center">90</td>
<td align="center">50 mg</td>
</tr>
<tr>
<td align="center" valign="bottom">50090-1232-0</td>
<td align="center">60</td>
<td align="center">100 mg</td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">50090-1305-0</td>
<td align="center">30</td>
<td align="center">150 mg</td>
</tr>
</tbody>
</table>
<p>
                     Repackaged by:<br><img alt="A-S Medication Solutions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=ASMLogo.jpg"><br>Libertyville, IL 60048</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 50090-1230-0</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="50090-1230-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=50090-1230-0.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 50090-1232-0</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="50090-1232-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=50090-1232-0.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 50090-1305-0</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="50090-1305-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6&amp;name=50090-1305-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LYRICA 		
					</strong><br><span class="contentTableReg">pregabalin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50090-1230(NDC:0071-1013)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREGABALIN</strong> (PREGABALIN) </td>
<td class="formItem">PREGABALIN</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;PGN;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50090-1230-0</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50090-1230-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021446</td>
<td class="formItem">12/30/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LYRICA 		
					</strong><br><span class="contentTableReg">pregabalin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50090-1232(NDC:0071-1015)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREGABALIN</strong> (PREGABALIN) </td>
<td class="formItem">PREGABALIN</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;PGN;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50090-1232-0</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021446</td>
<td class="formItem">12/30/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LYRICA 		
					</strong><br><span class="contentTableReg">pregabalin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50090-1305(NDC:0071-1016)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREGABALIN</strong> (PREGABALIN) </td>
<td class="formItem">PREGABALIN</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;PGN;150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50090-1305-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021446</td>
<td class="formItem">12/30/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">relabel(50090-1230), repack(50090-1230, 50090-1232, 50090-1305)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1b9d03bf-e697-4887-923f-888161eaf640</div>
<div>Set id: 59cf1b6b-eaae-4bd8-abca-8e68aeb30ee6</div>
<div>Version: 1</div>
<div>Effective Time: 20141215</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
